Myelin oligodendrocyte glycoprotein (MOG), a primary target autoantigen in an animal model of MS, is also known to have one N-glycosylation site at N31, and mutation at this site has led to autoantibody recognition in MS patients [71]. This evidence concerns the gene OMG and myeloid sarcoma.